Remove Funding Remove Layoffs Remove Startup Remove Study
article thumbnail

Biotech Roundup: Hellos, Goodbyes, “Cures” Delays And Trial News

Xconomy

The week started on a reflective note. And hellos: Third Rock Ventures brought in a well-traveled biotech veteran, Steven Holtzman , to run its hearing-loss startup Decibel Therapeutics. After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study.

News 40
article thumbnail

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

Xconomy

After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday.

Guide 63
article thumbnail

Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More

Xconomy

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Writing 56